Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 24Gastrointestinal 2CNS 1Breast 1

Conditions

Colorectal Neoplasms 17Pancreatic Neoplasms 11Carcinoma, Hepatocellular 10Colonic Neoplasms 7Rectal Neoplasms 6Ovarian Neoplasms 4Neoplasm Metastasis 4Cholangiocarcinoma 4Breast Neoplasms 4Prostatic Neoplasms 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Multiple Myeloma 2Lung Neoplasms 2Hematologic Neoplasms 2Gallbladder Neoplasms 2Fallopian Tube Neoplasms 2Esophageal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Urinary Bladder Neoplasms 1Turcot syndrome 1Thyroid Neoplasms 1Thrombocytosis 1Somatostatinoma 1Sarcoma 1Resectable Intrahepatic Cholangiocarcinoma 1Recurrence 1

Interventions

pembrolizumab 6Cisplatin 5Gemcitabine 4Specimen Handling 3Magnetic Resonance Spectroscopy 3Leucovorin 3Hyperthermic Intraperitoneal Chemotherapy 3Carboplatin 3130-nm albumin-bound paclitaxel 3veliparib 2aflibercept 2X-Rays 2Temozolomide 2Taxes 2SS1(dsFv)PE38 2Psychiatric Rehabilitation 2Polymerase Chain Reaction 2Oxaliplatin 2Nivolumab 2Irinotecan 2Interleukin-12 Subunit p35 2Immunoglobulin G 2Gene Expression Profiling 2Fluorouracil 2Drug Therapy 2Doxorubicin 2Disulfides 2Biopsy 2Bevacizumab 2Albumin-Bound Paclitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × Disulfides × Gastrointestinal × Clear all
NCT04673448 2026-01-09

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

University of Washington

Phase 1 Active not recruiting
18 enrolled
BreastGastrointestinalGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

NCT01010126 2019-01-25

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

National Cancer Institute (NCI)

Phase 2 Completed
252 enrolled 20 charts
GastrointestinalGynecologic

Fallopian Tube Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Somatostatinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡